Shire's successful Takhzyro study appears in JAMA

28 November 2018

The marketing drive for Shire’s (LSE: SHP) Takhzyro (lanadelumab) has had a boost as the company seeks to convince payers that its hefty price tag is worth paying.

Takhzyro this year became the first monoclonal antibody of its kind to be approved to treat hereditary angioedema (HAE) in the USA and Canada, but it does face competition from CSL Behring’s Haegarda (C1 esterase inhibitor).

Both therapies were found to exceed commonly cited thresholds for cost-effectiveness by the Institute for Clinical and Economic Review (ICER), so the Ireland-headquartered company needs to convince physicians of the benefits of treatment with Takhzyro.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK